Low MOQ for Phenylalanine Amino Acid - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex
Low MOQ for Phenylalanine Amino Acid - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:
Product Detail
| Name | Desmopressin |
| CAS number | 16679-58-6 |
| Molecular formula | C46H64N14O12S2 |
| Molecular weight | 1069.22 |
| EINECS Number | 240-726-7 |
| Specific rotation | D25 +85.5 ± 2° (calculated for the free peptide) |
| Density | 1.56±0.1 g/cm3(Predicted) |
| RTECS No. | YW9000000 |
| Storage conditions | Store at 0°C |
| Solubility | H2O:soluble20mg/mL, clear, colorless |
| Acidity coefficient | (pKa) 9.90±0.15 (Predicted) |
Synonyms
MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN
Indications
(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.
(2) Treatment of nocturnal enuresis (patients aged 5 years or older).
(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.
(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.
Treatment of diabetes insipidus
Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.
Product detail pictures:
Related Product Guide:
"Sincerity, Innovation, Rigorousness, and Efficiency" is the persistent conception of our company for the long-term to develop together with customers for mutual reciprocity and mutual benefit for Low MOQ for Phenylalanine Amino Acid - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Norway, California, Czech republic, We care about every steps of our services, from factory selection, product development & design, price negotiation, inspection, shipping to aftermarket. We have implemented a strict and complete quality control system, which ensures that each product can meet quality requirements of customers. Besides, all of our products have been strictly inspected before shipment. Your Success, Our Glory: Our aim is to help customers realize their goals. We are making great efforts to achieve this win-win situation and sincerely welcome you to join us.
By Eve from Seattle - 2017.10.23 10:29
After the signing of the contract, we received satisfactory goods in a short term, this is a commendable manufacturer.
By Jacqueline from Rotterdam - 2018.02.04 14:13
